Phase II studies of mitoxantrone (dihydroxyanthracenedione) in the treatment of advanced colorectal carcinoma

Am J Clin Oncol. 1984 Oct;7(5):517-22. doi: 10.1097/00000421-198410000-00024.


One hundred four patients with advanced colon carcinoma were treated with mitoxantrone 5 mg/m2 I.V. weekly. The patients were stratified into two groups: prior chemotherapy and no prior chemotherapy. Only one partial response was noted in the prior treatment category.

Publication types

  • Research Support, U.S. Gov't, P.H.S.

MeSH terms

  • Anthraquinones / adverse effects
  • Anthraquinones / therapeutic use*
  • Antineoplastic Agents / adverse effects
  • Antineoplastic Agents / therapeutic use*
  • Colonic Neoplasms / drug therapy*
  • Drug Evaluation
  • Humans
  • Mitoxantrone
  • Neoplasm Metastasis
  • Rectal Neoplasms / drug therapy*


  • Anthraquinones
  • Antineoplastic Agents
  • Mitoxantrone